Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2002-04-18
2010-06-29
Kwon, Brian-Yong S (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S547000
Reexamination Certificate
active
07745488
ABSTRACT:
A composition and method for promoting neutrophil survival and activation such as the treatment of neutropenia arising as an undesirable side effect of chemotherapy and radiation therapy. A composition containing medium-chain fatty acids, such as Capri acid or caprylic acid, or salts or triglycerides thereof, or mono- or diglycerides or other analogues thereof or medium-chain triglycerides (MCT) is administered to a human or animal needing treatment in an amount sufficient to reduce or eliminate neutropenia. The composition is administered in an amount effective to treat the disorder. The methods are also useful in the management of bone narrow transplantation and in the treatment of various neutropenic diseases.
REFERENCES:
patent: 4871768 (1989-10-01), Bistrian et al.
patent: 5011852 (1991-04-01), Park et al.
patent: 5214035 (1993-05-01), Veatch
patent: 5318781 (1994-06-01), Shah et al.
patent: 5431925 (1995-07-01), Ohmori et al.
patent: 5470861 (1995-11-01), Harmon
patent: 5549905 (1996-08-01), Mark et al.
patent: 5597562 (1997-01-01), Nomura et al.
patent: 5756474 (1998-05-01), Furstenau
patent: 5851534 (1998-12-01), Raheman et al.
patent: 6060459 (2000-05-01), von Borstel et al.
patent: 6113891 (2000-09-01), Burdick et al.
patent: 6136336 (2000-10-01), Tanaka et al.
patent: 6200602 (2001-03-01), Watts et al.
patent: 6267985 (2001-07-01), Chen et al.
patent: 6326360 (2001-12-01), Kanazawa et al.
patent: 6479540 (2002-11-01), Constantinides et al.
patent: 6725510 (2004-04-01), Clyburn
patent: 6835750 (2004-12-01), Henderson
patent: 6967028 (2005-11-01), Dulieu et al.
patent: 2002/0039595 (2002-04-01), Keller
patent: 2003/0211972 (2003-11-01), Backstrom et al.
patent: 2004/0052836 (2004-03-01), Li et al.
patent: 2004/0147599 (2004-07-01), Gagnon et al.
patent: 2006/0128800 (2006-06-01), Penney et al.
patent: 2008/0051324 (2008-02-01), Penney et al.
patent: 2008/0090848 (2008-04-01), Penney et al.
patent: 8-208510 (1995-10-01), None
patent: 10-265380 (1998-10-01), None
patent: WO 89/02275 (1989-03-01), None
patent: WO 95/30413 (1995-11-01), None
patent: WO 99/26640 (1999-06-01), None
patent: WO 99/45934 (1999-09-01), None
patent: WO 01/95914 (2001-12-01), None
patent: WO 02/083122 (2002-10-01), None
patent: WO 2004/069237 (2004-08-01), None
patent: WO 2005/012217 (2005-02-01), None
Keung et al., Gynecologic Oncology, vol. 61, pp. 448-450, 1996.
Yanai et al., Pharmaceutical Research, vol. 12, No. 5, pp. 653-657, 1995.
Henke et al., Radiotheapy and Oncology, 50, 1999, pp. 185-190.
Pierelli et al., Journal of Clinical Oncology, vol. 17, No. 4, 1999, pp. 1288-1295.
Miller, K., Leukemia Research 22, 1998, S13-S15.
Beau et al. “Comparison of bone marrow toxicity of medium-chain and long-chain triglyceride emulsions: An in vitro study in humans” XP-008007856 J. Parent. Ent. Nutri. 21:343-346 (1997).
Beers et al. “Leukopenia and lymphocytopenia” XP-002216068 The Merck Manual of Diagnosis and Therapy pp. 931-933 (1999).
Demirer et al. “Comparison of the efficacy of medium chain triglycerides with long chain triglycerides in total parenteral nutrition in patients with hematologic malignancies undergoing peripheral blood stem cell transplantation” XP-008007854 Clinical Nutrition 19:253-258 (2000).
Kimoto et al. “Antitumor effect of medium-chain triglyceride and its influence on the self-defense system of the body” XP-008007907 Cancer Detection and Prevention 22:219-224 (1998).
Pageau et al. “Systemic protection against radiation” XP-008007909 Radiat. Res. 66:267-273 (1976).
Reya et al. “Abnormal myelocity cell development in interleukin-2 (IL-2)-deficient mice: Evidence for the involvement of IL-2 in myelopoiesis” Blood 91:2935-2947 (1998).
Wanten et al. “Phagocytosis and killing ofCandida albicansby human neutrophils after exposure to structurally different lipid emulsions” XP-008007855 J. Parent. Ent. Nutrit. 25:9-13 (2001).
Wanten et al. “Nutritional lipid emulsions modulate cellular signaling and activation of human neutrophils” XP-008007838 J. Lipid Res. 42:428-436 (2001).
Wanten et al. “Saturated triglycerides and fatty acids activate neutrophils depending on carbon chain-length” XP-002215683 Eur. J. Clin. Invest. 32:285-289 (2002).
Yamada et al. “Hematopoietic stem cell proliferation accelerator” data base Accession No. 124:97756 HCA, XP-002215684 (1995).
Hisha et al. “Isolation and identification of hematopoietic stem cell-stimulating substances from kampo (Japanese herbal) medicine, Juzen-taiho-to” Blood vol. 90, No. 3, pp. 1022-1030, 1997.
Bach et al., “The Usefulness of Dietary Medium-Chain Triglycerides in Body Weight Control: Fact or Fancy?”Journal of Lipid Research, 1996, vol. 37, pp. 708-726.
Mizuno et al., “Effects of Salicylate and Other Enhancers on Rectal Absorption of Erythropoietin in Rats,”J. Pharm. Pharmacol., 1992, vol. 44, pp. 570-573.
Nijhof et al., “Isolation and Characterization of the Erythroid Progenitor Cell: CFU-E,”The Journal of Cell Biology, Feb. 1983, vol. 96, pp. 386-392.
Office Action issued in U.S. Appl. No. 10/544,350, dated Feb. 7, 2008.
Office Action issued in U.S. Appl. No. 10/544,350, dated Aug. 26, 2008.
Office Action issued in U.S. Appl. No. 10/544,350, dated Mar. 2, 2009.
Santos et al., “Improvement of norfloxacin oral bioavailability by EDTA and sodium caprate,”International Journal of Pharmaceutics, 2003, vol. 260, pp. 1-4.
Office Action issued in U.S. Appl. No. 10/544,350, dated Nov. 24, 2009.
Duffy, K., et al., “Hydrazinonaphthalene and Azonaphthalene Thrombopoietin Mimics Are Nonpeptidyl Promoters of Megakaryocytopoiesis,”J. Med. Chem., Sep. 13, 2001, pp. 3730-3745, vol. 44.
Duffy, K., et al., “Identification of a Pharmacophore for Thrombopoietic Activity of Small, Non-Peptidyl Molecules. 1. Discovery and Optimization of Salicylaldehyde Thiosemicarbazone Thrombopoietin Mimics,”J. Med. Chem., Jul. 19, 2002, pp. 3573-3575, vol. 45 (with Supporting Information attached).
Ito, K., et al., “Maitake beta-glucan enhances granulopoiesis and mobilization of granulocytes by increasing G-CSF production and modulating CXCR4/SDF-1 expression,”Int Immunopharmacol., Jun. 30, 2009, pp. 1189-1196, vol. 9, No. 10.
Kusano, K., et al., “A potential therapeutic role for small nonpeptidyl compounds that mimic human granulocyte colony-stimulating factor,”Blood, Sep. 25, 2003, pp. 836-842, vol. 103, No. 3.
Wang, Y., et al., “Role of the spleen in cyclophosphamide-induced hematosuppression and extramedullary hematopoiesis in mice,” Arch Med Res., Jun. 4, 2009, pp. 249-255, vol. 40, No. 4.
Barabe Jean
Gagnon Lyne
Laurin Pierre
Penney Christopher
Zacharie Boulos
Kwon Brian-Yong S
Prometic Biosciences Inc.
Saliwanchik Lloyd & Saliwanchik
LandOfFree
Medium-chain length fatty acids, glycerides and analogues as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Medium-chain length fatty acids, glycerides and analogues as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medium-chain length fatty acids, glycerides and analogues as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4248459